www.cbsnews.com
Recent studies show new antibody drugs can slow cognitive decline in early-onset Alzheimer’s, marking a critical breakthrough for the currently incurable disease. CBS’s Dr. Jon LaPook visited Washington University School of Medicine in St. Louis, where researchers are conducting pivotal clinical trials focused on treating the disease prior to symptom onset. These trials specifically target the 1 to 2 percent of Alzheimer’s patients with a genetic predisposition to dementia.
Additionally, LaPook interviewed philanthropist Bill Gates, who has committed $300 million to advance Alzheimer’s research. (96 words)
Read More
